Scancell Licenses CRT Antibody

Scancell Holdings and Cancer Research Technology, Ltd. (CRT) have signed an agreement under which Scancell has been granted a license to use a human antibody known as 105AD7. The antibody has previously been evaluated in clinical trials for osteosarcoma. Scancell’s worldwide license will be aimed at the development of new ImmunoBody vaccines for any immunotherapy indication. The license is limited to the use of the antibody as a framework for future vaccines.

Under the agreement, CRT will receive an upfront payment in addition to development milestone payments and royalties on future sales. Scancell will fund all development work, and will have sub-licensing rights on agreed terms.

Professor Lindy Durrant, chief executive officer of Scancell, said, “I am pleased that we have secured this important agreement with Cancer Research Technology. By utilizing antibody 105AD7, Scancell will be able to further enhance the clinical utility and safety of Scancell’s ImmunoBody platform both in cancer and other immunotherapy indications.”

Dr Phil L’Huillier, Cancer Research Technology’s director of business management, said, “Through this deal with Scancell we are able to take forward this antibody arising from research from our world-class scientists into commercial development to potentially make new vaccines to treat a range of diseases.”